Recruiting

Lynch Syndrome

Sponsor:

RWJ Barnabas Health at Jersey City Medical Center

Code:

NCT04516083

Conditions

Cancer Gene Mutation

Lynch Syndrome

Endometrial Cancer

Somatic Mutation

Eligibility Criteria

Sex: Female

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Mismatch repair instability somatic and germline testing

Study Details

Brief summary:

The objective of the study is the provide proof of high correlation between somatic and germline mismatch repair instability. This correlation is specifically researched in an area where patients have less access to cancer education and genetic testing for various reasons such as lack of insurance and general accessibility.

The study concentrates on early diagnosis of Lynch syndrome. Lynch syndrome is usually diagnosed from a blood test resulting in a mutation of one of the mismatch repair genes. Those are MLH1, MSH2, MSH 6, PMS2. A mutation in one of these genes creates a mismatch repair instability,hence higher incidence of cancers in specific organ groups. Amongst these organs are the Uterus, Ovaries, Upper genitourinary system, Pancreas and GI system.

The most common endometrial carcinoma which is found in Lynch syndrome is of endometrioid histology. Most patients with known germline mismatch repair instability, have the same somatic mutation. Our study is looking into correlating somatic mutation to germline mutation.

By doing so, patients diagnosed with somatic mismatch repair instability will be also diagnosed with lynch syndrome without germline genetic testing.

Screening programs will be utilized earlier and preventive procedures offered.

Due to less access to educational programs, genetic counseling and testing in underserved areas, patients are sometimes lost to follow up. Our study seeks to prove high correlation between somatic and germline mutations and by doing so, patient will be diagnosed with Lynch syndrome straight after endometrial cancer staging. As a result, increased compliance will be expected and patients will be offered the recommended preventative surgeries and screening protocols.

Conditions

Cancer Gene Mutation

Lynch Syndrome

Endometrial Cancer

Somatic Mutation

Study ID

NCT04516083

Start date

Dec 21, 2019

Status verified date

Aug, 2020

Completion date

Jun 30, 2021

Anticipated

Primary completion date

Dec 30, 2020

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Underserved areas. Diagnosis of endometrial endometrioid carcinoma. Low socioeconomic status. Positive mismatch repair staining. All races. All ages. All cancer grades. All cancer stages .

Exclusion Criteria:

Diagnosis of type 2 endometrial carcinoma. Cancer diagnosis other than Endometrial. No mismatch repair genes mutation. High socioeconomic status.

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Interventions

Mismatch repair instability somatic and germline testing

Each Endometrial Endometrioid adenocarcinoma is routinely stained for MMR mutation to seek for tumor genetic instability. If stains positive, the patient is called in for genetic blood testing to look for the same mutation in the germline.

Primary outcome measure

  • Number of patients who have a somatic mutation at the same time as a germline mutation [ Time Frame: Through study completion, an average of 18 months ]

Central Contacts and Locations

Central contacts

Locations

Jersey city medical center

Recruiting

Jersey City, New Jersey, United States, 07302

Contacts

More Information

Sponsor

RWJ Barnabas Health at Jersey City Medical Center

Last update posted

Aug 18, 2020

Last verified

Aug, 2020

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by RWJ Barnabas Health at Jersey City Medical Center on 2020-08-18.